There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. After-hours trades for Regenxbio Inc (RGNX) shows that investor sentiment remained same, with the stock’s consolidated last price to $17.74. The Regenxbio Inc has recorded 9,099 volume in the after hours trading session. The stock was recently discussed on Yahoo Finance as it revealed that REGENXBIO Announces Updated Strategic Plans and Third Quarter 2023 Financial Results.
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $17.74 and fluctuated between $17.91 as its day high and $17.33 as its day low. The current market capitalization of Regenxbio Inc is $780.38M. A total of 1.06 million shares were traded on the day, compared to an average of 406.77K shares.
Insider trades can also provide insight into a stock’s future direction. During the recent three months, RGNX has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 15 BUYs and 7 SELLs from insiders. Insiders purchased 456,218 shares during that period but sold 21,593.
In the most recent transaction, PAKOLA STEVE sold 3,138 shares of RGNX for 22.17 per share on Jan 03. After the transaction, the Chief Medical Officer now owns 12,175 company shares.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for RGNX in the last 3 months, the mean price target is $40.75 with high estimates of $65.00 and low estimates of $20.00. In terms of 52-week highs and lows, RGNX has a high of $25.54 and a low of $12.82.
As of this writing, RGNX has an earnings estimate of -$1.27 per share for the current quarter. EPS was calculated based on a consensus of 9 estimates, with a high estimate of -$0.77 per share and a lower estimate of -$1.64. The company reported an EPS of -$1.66 in the last quarter, which was -20.30% lower than expectations of -$1.38.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. RGNX’s latest balance sheet shows that the firm has $457.44M in Cash & Short Term Investments as of fiscal 2021. There were $86.68M in debt and $130.47M in liabilities at the time. Its Book Value Per Share was $8.25, while its Total Shareholder’s Equity was $764.30M.
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for RGNX is Buy with a score of 4.33.